Partnership Discovery Complete

Your Match Is In!

We found an exciting collaboration opportunity for you

Meet Your Potential Partner

WHOOP

Visit site

WHOOP is a wearable health and fitness platform that continuously monitors physiological data to provide personalised insights on recovery, sleep, and performance. In March 2026, WHOOP raised $575 million in Series G funding at a $10.1 billion valuation, with investors including LeBron James and Cristiano Ronaldo. Its screenless wristband tracks heart rate variability, respiratory rate, sleep stages, and skin temperature, while its AI coaching engine translates raw data into actionable behavioural guidance. The recently launched Healthspan suite introduces metrics like WHOOP Age — a biological age score derived from longitudinal physiological trends — positioning the company at the intersection of consumer fitness and longevity science. With over 2.5 million members globally and 103% year-over-year growth in 2025, WHOOP is expanding from elite athletes to mainstream health-conscious consumers.

WHOOP is the strongest cross-industry partner for Novo Nordisk because it turns continuous physiological data into behavior change, which complements Novo Nordisk’s medicines for obesity, diabetes, and cardiometabolic disease. Novo brings clinically validated therapies, disease expertise, and patient pathways; WHOOP brings a highly engaged consumer base, always-on biometrics, and an AI coaching layer that can reinforce medication adherence, exercise, sleep, and recovery habits. Together, they can create a medication-plus-behavior ecosystem that improves outcomes, deepens patient engagement, and generates longitudinal real-world evidence around weight, glucose-related risk, sleep, and cardiometabolic health.

Health Tech
Wearables
Longevity
Patient Support
Real-World Evidence

Share this match

Want the full report?

Why we matched

WHOOP is not just another health app; it is a behavior and biometrics engine with a large, motivated user base already focused on performance, recovery, and longevity. That makes it far more complementary to Novo Nordisk than a generic software partner. Novo Nordisk’s biggest challenge in obesity and diabetes is not only drug efficacy, but sustained adherence, lifestyle reinforcement, and long-term outcomes tracking. WHOOP directly addresses those gaps with continuous data and coaching, while Novo adds clinical credibility, disease-state expertise, and therapies that can materially improve health. The combination creates a differentiated, outcomes-oriented offering that can be sold to clinicians, employers, and payers—and it can generate valuable evidence on how medication and daily behavior work together in cardiometabolic care.

Confidence: 90%

Collaboration Opportunities

  1. 1

    Launch a Novo Nordisk + WHOOP cardiometabolic support program for Wegovy and diabetes patients: enroll adults starting treatment into a 12-week digital companion that tracks sleep, recovery, activity, resting heart rate, and consistency of routines, then delivers weekly coaching nudges tied to medication milestones (for example, first 30 days on treatment, dose escalation week, plateau management).

  2. 2

    Build an outcomes-based real-world evidence study using WHOOP longitudinal data to measure changes in recovery, sleep regularity, and activity adherence alongside clinical endpoints such as weight loss trajectory, HbA1c reduction, and persistence on therapy over 6–12 months.

  3. 3

    Create a physician-recommended premium patient support bundle: Novo Nordisk provides onboarding, disease education, and medication support; WHOOP provides the daily adherence and lifestyle layer. This can be positioned through obesity clinics, endocrinology practices, and employer health programs.

  4. 4

    Co-market a cardiometabolic health campaign targeting health-conscious adults at elevated risk of obesity or prediabetes, using WHOOP’s data-rich user journey to identify segments most likely to benefit from preventive intervention and Novo Nordisk to offer medically guided next-step pathways.

  5. 5

    Develop a population health pilot with employers or payers: employees on GLP-1 therapy get WHOOP membership plus Novo digital support, with the employer/payer tracking aggregate engagement, absenteeism proxy metrics, and downstream medical-cost indicators over a 6–9 month pilot.

Next Steps & Implementation

  1. 1

    Within 2 weeks, align on a joint pilot scope: one obesity clinic network in the US and one in Europe, with 500–1,000 patients starting Wegovy or related care pathways.

  2. 2

    Within 30 days, define the data model and governance: decide which WHOOP signals (sleep duration, strain, recovery, HRV trends) will be shared, how consent will work, and what outcomes Novo can evaluate for real-world evidence.

  3. 3

    Within 45 days, design the intervention: a branded patient journey with specific nudges at day 1, week 2, week 6, and each dose titration point, plus escalation rules for low adherence or stalled progress.

  4. 4

    Within 60 days, launch the first cohort and run a 12-week readout covering medication persistence, app engagement, activity changes, and early weight-change trends.

  5. 5

    Within 90 days, package results into a joint payer/employer case study and a clinician-facing deck showing how continuous recovery and sleep data can improve medication-supported weight management and diabetes care.

Ready to make the Novonordisk × WHOOP partnership happen?

Hyperadvancer strategists have turned roulette results into reality for bold companies. Book a 30-minute call to explore yours.

Emergency partnership hotline

Ready to revolutionise commerce as we know it? Drop us a line.